Related Experiment Video

Updated: Jun 12, 2026

An Improved and High Throughput Respiratory Syncytial Virus (RSV) Micro-neutralization Assay
09:14

An Improved and High Throughput Respiratory Syncytial Virus (RSV) Micro-neutralization Assay

Published on: January 26, 2019

Cost-effectiveness of palivizumab in infancy

Nicholas D Embleton1, Sandeep T Dharmaraj, Sanjeev Deshpande

  • 1Newcastle Neonatal Service, Royal Victoria Infirmary, Newcastle upon Tyne, NE1 4LP, UK. n.d.embleton@ncl.ac.uk.

Expert Review of Pharmacoeconomics & Outcomes Research
|June 10, 2010
PubMed

Insights

Palivizumab can reduce hospitalizations for respiratory syncytial virus (RSV) in high-risk infants. However, its cost-effectiveness requires careful analysis due to data limitations and variable cost assessments.

Area of Science:

  • Pediatrics
  • Infectious Diseases
  • Health Economics

Background:

  • Respiratory syncytial virus (RSV) is a leading cause of infant bronchiolitis and rehospitalization in the UK.
  • Palivizumab, a monoclonal antibody, is approved for preventing RSV in high-risk infants.
  • Existing economic analyses of palivizumab show significant cost discrepancies.

Purpose of the Study:

  • To review limitations in palivizumab efficacy and economic data.
  • To address challenges in interpreting and extrapolating existing data.
  • To present a UK-specific cost-effectiveness analysis for high-risk infants.

Main Methods:

  • Literature review of palivizumab efficacy and economic studies.
  • Critical analysis of data interpretation and extrapolation issues.
  • Cost-effectiveness analysis tailored to UK high-risk infant populations.

Main Results:

  • Identified significant limitations in current palivizumab efficacy and economic data.
  • Highlighted challenges in applying existing data to diverse populations.
  • Conducted a cost-effectiveness analysis specific to UK high-risk infants.

Conclusions:

  • Further research is needed to address data limitations for palivizumab.
  • Careful interpretation and extrapolation of economic data are crucial.
  • The cost-effectiveness of palivizumab in the UK requires a nuanced, population-specific evaluation.

More Related Videos

Development of an IFN-γ ELISpot Assay to Assess Varicella-Zoster Virus-specific Cell-mediated Immunity Following Umbilical Cord Blood Transplantation08:04

Development of an IFN-γ ELISpot Assay to Assess Varicella-Zoster Virus-specific Cell-mediated Immunity Following Umbilical Cord Blood Transplantation

Published on: July 9, 2014

Noninvasive Sampling of Mucosal Lining Fluid for the Quantification of In Vivo Upper Airway Immune-mediator Levels05:31

Noninvasive Sampling of Mucosal Lining Fluid for the Quantification of In Vivo Upper Airway Immune-mediator Levels

Published on: August 7, 2017

Related Concept Videos

Respiratory Syncytial Virus Disease01:29

Respiratory Syncytial Virus Disease

Human respiratory syncytial virus (RSV) is a widespread pathogen that primarily targets infants and young children but also poses a serious health risk to elderly and immunocompromised individuals. Belonging to the Pneumoviridae family, RSV is a negative-sense, single-stranded RNA virus within the Pneumovirus genus. Its global health burden is significant, with millions of cases annually resulting in hospitalizations and mortality, particularly in resource-limited settings. Although most...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Poliomyelitis01:17

Poliomyelitis

Poliomyelitis is caused by poliovirus, a small, non-enveloped, positive-sense RNA virus of the Picornaviridae family and Enterovirus genus. Transmission occurs primarily via the fecal-oral route, often through ingestion of contaminated water or food. The virus initially replicates in the oropharynx and intestinal mucosa, particularly in lymphoid tissues such as the tonsils, Peyer’s patches, and regional lymph nodes. Primary viremia follows, allowing dissemination throughout the body.In most...
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Asthma-IV: Nursing Management01:30

Asthma-IV: Nursing Management

The nursing management of asthma is a comprehensive approach that relies heavily on the expertise and dedication of healthcare professionals. It involves thorough assessment, accurate diagnosis, strategic planning, effective implementation, and diligent evaluation. By meticulously following this step-by-step process, healthcare professionals play a crucial role in providing the best possible care and treatment for patients with asthma, enhancing their overall health and well-being.
First, in...